BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hope in Focus - ECPv6.15.13//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://old.hopeinfocus.org
X-WR-CALDESC:Events for Hope in Focus
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20220324T130000
DTEND;TZID=UTC:20220324T140000
DTSTAMP:20260521T123648
CREATED:20220321T124948Z
LAST-MODIFIED:20220321T125017Z
UID:1708-1648126800-1648130400@old.hopeinfocus.org
SUMMARY:Let's Chat About...Opus Genetics
DESCRIPTION:Ben Yerxa\, Co-Founder & President\, Opus Genetics\n\nLet’s Chat About … Opus Genetics \n \nBen Yerxa\, PhD\, is Co-Founder & President of Opus Genetics. Founded in 2021\, Opus Genetics is a patient-first\, science-driven gene therapy company tackling manufacturing obstacles standing in the way of treatments for ultra-rare blinding conditions. Dr. Yerxa will speak about the Opus Genetics’ business model\, pipeline\, manufacturing process\, and their focus on tried and true methods. \nAbout Benjamin Yerxa\, PhD\nFoundation Fighting Blindness \nAs its Chief Executive Officer\, Dr. Yerxa is responsible for the overall management of the Foundation Fighting Blindness\, the world’s leading private funder of research on potential treatments and cures for inherited retinal degenerative diseases including age-related macular degeneration. He also serves as CEO of the Retinal Degeneration Fund\, a wholly owned\, not-for-profit subsidiary focused on making venture philanthropy investments to further the Foundation’s mission. Dr. Yerxa has more than 25 years’ experience in biotechnology\, drug development\, and in translating promising research discoveries into clinical milestones and treatments. His experience\, from drug discovery through product launches and in leadership positions\, is in the pulmonary\, oral health\, cardiovascular\, HIV\, and ophthalmology fields. Just before joining the Foundation\, Dr. Yerxa was president and co-founder of Envisia Therapeutics\, a company focused on developing novel ocular sustained delivery therapies for the front and back of the eye. Dr. Yerxa holds 60 U.S. patents. An inventor of DIQUAS™\, an innovative treatment for dry eye approved in Japan\, he has been involved in the discovery and development of investigational new drugs\, Phase 3 clinical programs\, new drug applications\, and drug approvals. Dr. Yerxa earned his PhD in organic chemistry from University of California\, Irvine\, and BA in chemistry from the University of California\, San Diego. \nREGISTER\n  \nHope in Focus is proud to bring our web series “Let’s Chat About …” to the Leber congenital amaurosis and rare inherited retinal disease communities. We’ve developed the series with those living with LCA and IRDs in mind\, but we invite all members of our community\, including those in research\, industry\, and the regulatory communities to join any of the sessions\, as we look ahead to a common goal of advancing treatments for rare retinal disease.
URL:https://old.hopeinfocus.org/event/lets-chat-about-opus-genetics/
CATEGORIES:Let's Chat About ...
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220316T130000
DTEND;TZID=UTC:20220316T140000
DTSTAMP:20260521T123648
CREATED:20220224T170153Z
LAST-MODIFIED:20220224T190008Z
UID:1666-1647435600-1647439200@old.hopeinfocus.org
SUMMARY:Let's Chat About ... Self-Advocacy and Supporting Your Child's Education
DESCRIPTION:Beth Borysewicz\, State of CT Department of Aging and Disability Services; Bureau of Ed. Services for the Blind\n\nLet’s Chat About … Self-Advocacy in the Classroom \n \nBeth Borysewicz is the Vice Chair on the Hope in Focus Board of Directors\, and is an Education Consultant for the Department of Aging and Disabilities\, Bureau of Education Services for the Blind. Beth found her passion working with the blind and low vision community unexpectedly when she had a 3 year old named Sofia in her class 16 years ago diagnosed with LCA. As a Teacher of Students with Visual Impairments\, she has focused her career on teaching her students self-advocacy and exploring the Expanded Core Curriculum in fun and exciting ways. \nBeth also authors her own blog dedicated to professionals\, families and students titled\, I Love Brl (Braille) https://ilovebrl.com \nREGISTER\n  \nHope in Focus is proud to bring our web series “Let’s Chat About …” to the Leber congenital amaurosis and rare inherited retinal disease communities. We’ve developed the series with those living with LCA and IRDs in mind\, but we invite all members of our community\, including those in research\, industry\, and the regulatory communities to join any of the sessions\, as we look ahead to a common goal of advancing treatments for rare retinal disease.
URL:https://old.hopeinfocus.org/event/lets-chat-about-self-advocacy-in-the-classroom/
CATEGORIES:Let's Chat About ...
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220118T130000
DTEND;TZID=America/New_York:20220118T140000
DTSTAMP:20260521T123648
CREATED:20210217T175730Z
LAST-MODIFIED:20220104T223936Z
UID:1402-1642510800-1642514400@old.hopeinfocus.org
SUMMARY:Let’s Chat About … ProQR's work in treatments for inherited retinal disease
DESCRIPTION:Hope in Focus is proud to bring our web series “Let’s Chat About …” to the Leber congenital amaurosis and rare inherited retinal disease communities. We’ve developed the series with those living with LCA and IRDs in mind\, but we invite all members of our community\, including those in research\, industry\, and the regulatory communities to join any of the sessions\, as we look ahead to a common goal of advancing treatments for rare retinal disease. \nRegister for Free\nDaniel de Boer\, Founder and Chief Executive Officer\, ProQR Therapeutics\n\nLet’s Chat About … ProQR’s work in treatments for inherited retinal disease \nDaniel de Boer is Founder and Chief Executive Officer of ProQR\, which was incorporated in 2012. Daniel is a serial entrepreneur and passionate advocate for rare disease patients. After one of his children was diagnosed with a rare disease\, he started ProQR to develop RNA therapies for rare diseases. Under Daniel’s leadership\, ProQR developed a platform that yielded a diversified pipeline of potential treatments for rare diseases and raised more than $400M in funding\, including an IPO on Nasdaq. Before founding ProQR\, Daniel was founder and Chief Executive Officer of several technology companies. Daniel is also co-founder and strategic advisor to Amylon Therapeutics and Wings Therapeutics\, strategic advisor at Frame Therapeutics\, Meatable\, Algramo and a member of the advisory board at the Termeer Foundation. In 2018 Daniel was named “Emerging Entrepreneur of the Year” by EY. In 2019 Daniel was selected for the Young Global Leader program at the World Economic Forum.
URL:https://old.hopeinfocus.org/event/lets-chat-about-proqrs-work-in-treatments-for-inherited-retinal-disease/
CATEGORIES:Let's Chat About ...
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20211208T130000
DTEND;TZID=UTC:20211208T140000
DTSTAMP:20260521T123648
CREATED:20211105T132300Z
LAST-MODIFIED:20211118T124510Z
UID:1564-1638968400-1638972000@old.hopeinfocus.org
SUMMARY:Let's Chat About ... Gene Therapy for LCA
DESCRIPTION:Join us as we chat with Michel Michaelides\, (BSc MB BS MD(Res) FRCOphth FACS) a Founding Member of MeiraGTx and Professor of Ophthalmology\, UCL Institute of Ophthalmology in Dept. of Genetics. He is a Consultant Ophthalmologist at Moorfields Eye Hospital in Depts. Of Inherited Eye Disease\, Medical Retina and Paediatric Ophthalmology.\n\nMeiraGTX saw statistically significant improvement demonstrated in vision-guided mobility and visual function in treated eyes compared to untreated eyes during its Phase 1/2 clinical trial of AAV-RPE65 in both adult and pediatric patients with RPE65-deficiency.\n\nRegister here: https://na.eventscloud.com/ereg/newreg.php?eventid=643280&
URL:https://old.hopeinfocus.org/event/lets-chat-about-gene-therapy-for-lca/
CATEGORIES:Let's Chat About ...
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20211018T130000
DTEND;TZID=UTC:20211018T140000
DTSTAMP:20260521T123648
CREATED:20210809T141217Z
LAST-MODIFIED:20210809T141302Z
UID:1483-1634562000-1634565600@old.hopeinfocus.org
SUMMARY:Let's Chat About ... CRISPR and gene editing technology
DESCRIPTION:Sofia Sees Hope is proud to bring our web series “Let’s Chat About …” to the Leber congenital amaurosis and rare inherited retinal disease communities. We’ve developed the series with those living with LCA and IRDs in mind\, but we invite all members of our community\, including those in research\, industry\, and the regulatory communities to join any of the sessions\, as we look ahead to a common goal of advancing treatments for rare retinal disease. \n\nMonica Roy is Vice President\, Clinical Development-Ophthalmology for Editas Medicine. She has focused her career on ophthalmic drug development. She has led teams through all phases of clinical development\, regulatory approval\, commercial launch\, and life cycle management. Her experience includes leading the development of ophthalmic gene therapy programs for age related macular degeneration and diabetic retinopathy\, leading the successful approval of Xiidra for dry eye disease\, and most recently leading gene editing programs in inherited retinal disease. \nCurrently Editas is in trials with EDIT-101\, a CRISPR-based experimental medicine under investigation for the treatment of Leber congenital amaurosis 10 (LCA10) (CEP290). \n\n  \n  \n 
URL:https://old.hopeinfocus.org/event/lets-chat-about-crispr-and-gene-editing-technology/
CATEGORIES:Let's Chat About ...
ATTACH;FMTTYPE=image/jpeg:https://old.hopeinfocus.org/wp-content/uploads/2021/01/lets_chat_about_web_banner.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20210929T130000
DTEND;TZID=UTC:20210929T140000
DTSTAMP:20260521T123648
CREATED:20210721T172414Z
LAST-MODIFIED:20210721T172414Z
UID:1474-1632920400-1632924000@old.hopeinfocus.org
SUMMARY:Let's Chat About ... the importance of the patient voice in rare disease
DESCRIPTION:Sofia Sees Hope is proud to bring our web series “Let’s Chat About …” to the Leber congenital amaurosis and rare inherited retinal disease communities. We’ve developed the series with those living with LCA and IRDs in mind\, but we invite all members of our community\, including those in research\, industry\, and the regulatory communities to join any of the sessions\, as we look ahead to a common goal of advancing treatments for rare retinal disease. \n\nJill Dolgin\, PharmD\, Head of Patient Advocacy\, Applied Genetic Technologies\nCorporation (AGTC)\n\n\nLet’s Chat About … the importance of the patient voice in rare disease. \n\nDr. Dolgin leads the patient and professional engagement strategy to drive disease awareness and clinical trial recruitment\nefforts for the AGTC pipeline. She is responsible for incorporating the voice of the patient throughout drug development and corporate culture. She has over 20 years of global biopharmaceutical experience in Medical Affairs\, Corporate Communications\, Patient and Professional Advocacy\, and Public Policy. \nHer role within the company is to ensure that the needs of the patients are considered and incorporated into every aspect of drug development. Externally\, Jill works with patient advocacy groups to educate patients and families about the importance of participating in clinical trials\, gene therapy and the importance of “getting your voices heard” to help consumers\, healthcare professionals\, and policy makers understand your challenges in living with your disease. Dr. Dolgin earned a Doctorate in Clinical Pharmacy from the University of the Sciences at Philadelphia and a Bachelor of Science degree in Pharmacy from The Ohio State University.
URL:https://old.hopeinfocus.org/event/lets-chat-about-the-importance-of-the-patient-voice-in-rare-disease/
CATEGORIES:Let's Chat About ...
ATTACH;FMTTYPE=image/jpeg:https://old.hopeinfocus.org/wp-content/uploads/2021/01/lets_chat_about_web_banner.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20210616T190000
DTEND;TZID=UTC:20210616T200000
DTSTAMP:20260521T123648
CREATED:20210408T180220Z
LAST-MODIFIED:20210408T180220Z
UID:1430-1623870000-1623873600@old.hopeinfocus.org
SUMMARY:Let’s Chat About … The Importance of Self Advocacy
DESCRIPTION:Sofia Sees Hope is proud to bring our web series “Let’s Chat About …” to the Leber congenital amaurosis and rare inherited retinal disease communities. We’ve developed the series with those living with LCA and IRDs in mind\, but we invite all members of our community\, including those in research\, industry\, and the regulatory communities to join any of the sessions\, as we look ahead to a common goal of advancing treatments for rare retinal disease.\n\n\nToday we chat with Tami Morehouse and Jack McCormick about self advocacy in the rare disease community.\n\n\nTami Morehouse made research history when at age 44\, she participated in a clinical trial for gene therapy for LCA2 (RPE65). Ultimately\, Spark Therapeutics developed the drug that was marketed as LUXTURNA® following Federal Drug Administration approval in December 2017. Tami volunteers in Sofia Sees Hope’s Family Connections program\, which connects people within the LCA community to share information and provide support. She is also an SSH Ambassador. Our Ambassadors give encouragement to LCA patients and caregivers\, they attend conferences\, keep up with research\, and share their stories and experiences to help others.\n\n\nJack McCormick of Ontario\, Canada\, graduated from Wilfrid Laurier University in Waterloo\, Ontario\, in 2018. Diagnosed with LCA2 due to a mutation in his RPE65 gene\, Jack is a passionate advocate for inclusion and accessibility on all fronts. He initially tried to hide his blindness but that all ended when he got Jake\, his beloved guide dog. In college he founded Eye To Eye\, a student club whose goal is to illuminate stigma associated with vision impairments. He volunteers with Fighting Blindness Canada\, including working on the 2018 Young Leaders Summit.\n\n\nHe is an organizational development consultant in the healthcare industry\, is board vice chair of CNIB ON/QC and serves on the Metrolinx Accessibility Committee. In 2021\, he launched the Lights with Jack McCormic‪k podcast\, what he describes as “my attempt to unlock the secrets to living a more meaningful and fulfilling life so that together we can find the lights in our life. Thank you for joining me as we connect with business leaders\, personal development experts and inspiring people with stories to tell.”\n\n\nREGISTER
URL:https://old.hopeinfocus.org/event/lets-chat-about-the-importance-of-self-advocacy/
CATEGORIES:Let's Chat About ...
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20210513T130000
DTEND;TZID=UTC:20210513T140000
DTSTAMP:20260521T123648
CREATED:20210217T174449Z
LAST-MODIFIED:20210217T174449Z
UID:1400-1620910800-1620914400@old.hopeinfocus.org
SUMMARY:Let's Chat About ... My Retina Tracker
DESCRIPTION:Sofia Sees Hope is proud to bring our web series “Let’s Chat About …” to the Leber congenital amaurosis and rare inherited retinal disease communities. We’ve developed the series with those living with LCA and IRDs in mind\, but we invite all members of our community\, including those in research\, industry\, and the regulatory communities to join any of the sessions\, as we look ahead to a common goal of advancing treatments for rare retinal disease. \n\n\nTodd A. Durham\, MS\, PhD\nVice President\, Clinical & Outcomes Research\, Foundation Fighting Blindness\n\n\nLet’s Chat About … My Retina Tracker \nTodd Durham is the Vice President\, Clinical & Outcomes Research at the Foundation Fighting Blindness\, a national non-profit that funds research to treat and cure inherited retinal diseases. In his current role\, Todd is responsible for directing the Foundation’s Clinical Consortium of retinal experts\, developing strategies to enhance product development\, partnering with industry\, and providing technical input on partnered programs and investment decisions.  Todd has over 25 years of drug development experience. Prior to his current position\, he contributed to research on numerous marketed products as Director of Biostatistics with IQVIA’s Real World Evidence Solutions\, was a doctoral fellow with Bristol Myers Squibb\, and worked in various statistical and leadership roles for Novan\, Inspire Pharmaceuticals\, Quintiles\, and as a self-employed consultant.  Todd earned a BSPH and MS in biostatistics and a PhD in health policy and management (Decision Science and Outcomes Research) from the UNC Gillings School of Global Public Health.
URL:https://old.hopeinfocus.org/event/lets-chat-about-my-retina-tracker/
CATEGORIES:Let's Chat About ...
ATTACH;FMTTYPE=image/jpeg:https://old.hopeinfocus.org/wp-content/uploads/2021/01/lets_chat_about_web_banner.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20210419T130000
DTEND;TZID=UTC:20210419T140000
DTSTAMP:20260521T123648
CREATED:20210125T163640Z
LAST-MODIFIED:20210125T163640Z
UID:1380-1618837200-1618840800@old.hopeinfocus.org
SUMMARY:Let’s Chat About … natural history and patient outcome studies
DESCRIPTION:Sofia Sees Hope is proud to bring our web series “Let’s Chat About …” to the Leber congenital amaurosis and rare inherited retinal disease communities. We’ve developed the series with those living with LCA and IRDs in mind\, but we invite all members of our community\, including those in research\, industry\, and the regulatory communities to join any of the sessions\, as we look ahead to a common goal of advancing treatments for rare retinal disease. \n\nJonathan Stokes\, Director\, Patient-Centered Outcomes Research\, abbvie\n\n\nLet’s Chat About … Why natural history and patient outcome studies are important. \n\nJonathan Stokes \n\n\nJonathan has a devoted interest in understanding and bringing to light the patient voice and perspective\, with more than 16 years of research study design and implementation experience. His experience is primarily in health outcomes research; specifically\, the development and evaluation of clinical outcomes of assessment (COAs) for use in clinical trials intended to substantiate product labeling goals\, as well as use of COAs in real world clinical practice. Areas of focus include the evaluation of cardinal signs and symptoms of disease\, health-related quality of life\, improvements and activation in treatment adherence\, understanding unmet need\, and exploring the burden of disease. \nREGISTER
URL:https://old.hopeinfocus.org/event/lets-chat-about-natural-history-and-patient-outcome-studies/
CATEGORIES:Let's Chat About ...
ATTACH;FMTTYPE=image/jpeg:https://old.hopeinfocus.org/wp-content/uploads/2021/01/lets_chat_about_web_banner.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210315T130000
DTEND;TZID=America/New_York:20210315T140000
DTSTAMP:20260521T123648
CREATED:20210122T185153Z
LAST-MODIFIED:20210122T185153Z
UID:1374-1615813200-1615816800@old.hopeinfocus.org
SUMMARY:Let's Chat About ... Genetic Testing
DESCRIPTION:Sofia Sees Hope is proud to bring our web series “Let’s Chat About …” to the Leber congenital amaurosis and rare inherited retinal disease communities. We’ve developed the series with those living with LCA and IRDs in mind\, but we invite all members of our community\, including those in research\, industry\, and the regulatory communities to join any of the sessions\, as we look ahead to a common goal of advancing treatments for rare retinal disease. \n\nEmily Place\, Licensed Genetic Counselor and Research Study Coordinator\, Massachusetts Eye and Ear\n\n\nLet’s Chat About … genetic testing. \n\nEmily Place \n\n\nPrior to working at the Ocular Genomics Institute at Mass Eye and Ear\, Place worked as a pediatric genetic counselor at The Children’s Hospital of Philadelphia. She joined the OGI in 2011\, where she provides risk assessment and genetic counseling services to families with inherited retinal dystrophies. She also serves as the study coordinator for the research study of molecular genetics of inherited retinal dystrophies. \nREGISTER
URL:https://old.hopeinfocus.org/event/lets-chat-about-genetic-testing/
CATEGORIES:Let's Chat About ...
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210216T150000
DTEND;TZID=America/New_York:20210216T160000
DTSTAMP:20260521T123648
CREATED:20210122T184235Z
LAST-MODIFIED:20210216T181255Z
UID:1372-1613487600-1613491200@old.hopeinfocus.org
SUMMARY:Let's Chat About: FDA Review of Rare Retinal Disease Treatments
DESCRIPTION:Sofia Sees Hope is proud to bring our web series “Let’s Chat About …” to the Leber congenital amaurosis and rare inherited retinal disease communities. We’ve developed the series with those living with LCA and IRDs in mind\, but we invite all members of our community\, including those in research\, industry\, and the regulatory communities to join any of the sessions\, as we look ahead to a common goal of advancing treatments for rare retinal disease. \n\nWiley Chambers\, MD\, Supervisory Medical Officer\, Office of New Drugs\, Center for Drug Evaluation and Research\, U.S. Food and Drug Administration (FDA)\n\n\nLet’s Chat About … What it takes to receive approval for retinal disease treatments from the FDA. \n\nWiley Chambers \n\n\nDr. Chambers joined the FDA in 1987\, as a primary reviewer for ophthalmic drug products and in 1990 became a Supervisory Medical Officer for Ophthalmologic Drug Products. In this capacity\, Dr. Chambers has supervisory responsibility for the clinical review of ophthalmologic drug products and ophthalmic therapeutic biologic products submitted to the Center for Drug Evaluation and Research.  He is currently a Clinical Professor of Ophthalmology and Adjunct Assistant Professor of Computer Medicine at The George Washington University. \nREGISTER
URL:https://old.hopeinfocus.org/event/fda-review-of-rare-retinal-disease-treatments/
CATEGORIES:Let's Chat About ...
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20210127T130000
DTEND;TZID=UTC:20210127T140000
DTSTAMP:20260521T123648
CREATED:20210119T190952Z
LAST-MODIFIED:20210119T192501Z
UID:1366-1611752400-1611756000@old.hopeinfocus.org
SUMMARY:Webinar: Let's Chat About ... the Latest in LCA Therapy Research
DESCRIPTION:Sofia Sees Hope is proud to bring our web series “Let’s Chat About …” to the Leber congenital amaurosis and rare inherited retinal disease communities. We’ve developed the series with those living with LCA and IRDs in mind\, but we invite all members of our community\, including those in research\, industry\, and the regulatory communities to join any of the sessions\, as we look ahead to a common goal of advancing treatments for rare retinal disease. \n\nBen Shaberman\, Senior Director\, Scientific Outreach & Community Engagement\, Foundation Fighting Blindness\n\n\nLet’s Chat About … What’s in the therapy pipeline for Leber congenital amaurosis. \nBen Shaberman \nFor 16 years\, Ben has been reporting on retinal research for all of FFB’s electronic and print publications. In addition\, he presents the latest scientific advancements at local and national events for patients and families\, and conducts various training activities for staff and constituents. He enjoys working with constituents one-on-one to help them understand their retinal disease and the research underway that may benefit them. Ben also leads the company’s outreach to eye care professionals throughout the United States. \nREGISTER
URL:https://old.hopeinfocus.org/event/webinar-lets-chat-about-the-latest-in-lca-therapy-research/
CATEGORIES:Let's Chat About ...
ATTACH;FMTTYPE=image/jpeg:https://old.hopeinfocus.org/wp-content/uploads/2021/01/lets_chat_about_web_banner.jpg
END:VEVENT
END:VCALENDAR